Giugliano, Robert P <br/><br/>
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.  [electronic resource] 

 -  Lancet (London, England)  Dec 2012 
 - 2007-17 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(12)61770-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Analysis of Variance<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--administration & dosage<br/>Azetidines--administration & dosage<br/>Cholesterol, HDL--blood<br/>Cholesterol, LDL--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Ezetimibe<br/>Female<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--administration & dosage<br/>Hypercholesterolemia--drug therapy<br/>Immunoglobulin G--immunology<br/>Male<br/>Middle Aged<br/>Proprotein Convertase 9<br/>Proprotein Convertases--antagonists & inhibitors<br/>Serine Endopeptidases--immunology<br/>Treatment Outcome<br/>Young Adult